INTRODUCTION
============

Risk evaluation underlies everyday decisions from the mundane to the more substantial: should I walk today, switch careers? Risk attitude varies as a function of probability and valence in a nonlinear fashion thus varying as a function of context. The pathological use of exogenous drugs or natural food rewards are behaviors characterized by the evaluation of risk. The likelihood of obtaining reward is weighted against the likelihood of punishment in the form of social or financial losses or poor health. Here we assess the relationship between risk and the influence of probability, valence (ie, gain or loss), and magnitude (value) across pathological behaviors toward drug and food rewards.

Prospect theory and experimental evidence demonstrate a fourfold pattern of risk attitude that varies as a function of the nonlinearity of probability weighting and valence ([@bib9]) ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). An outcome value is weighted by a decision weight, *w(p)*, ie, the subjective belief of the objective probability *p*. Probability influences risk attitudes. This is because outcomes with lower probabilities are overweighted and thus perceived as more probable, leading to risk-seeking for gains (eg, buying lotteries) and risk aversion for losses of low probability (eg, buying insurance). On the other hand, higher probabilities are underweighted, causing risk aversion for gains and risk-seeking for losses of high probability. This nonlinearity of probability weighting has been associated with anterior cingulate activity ([@bib17]) and D1 receptor activity ([@bib24]). Risk evaluation is also affected by subjective value, which has a concave function, reflecting diminishing subjective discrimination (marginal sensitivity) ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). Thus, a £10 increment at a higher magnitude, £1000 and £1010, has less subjective value than the same increment at a lower magnitude, £10 and £20.

We focus on risk-taking attitude across disorders of pathological choice involving natural (obese subjects with and without binge eating disorder (BED)) and drug rewards (abstinent alcohol and stimulant dependence). Although losses in the form of social and health cost are difficult to model, the secondary reinforcer of money can act as a proxy. The rodent model of sucrose binge eating has many similarities with models of substance-use disorders ([@bib1]), suggesting that the pattern of food intake, namely binge eating, is a crucial subtype and may differentiate obese subjects with and without binge eating. Although preclinical evidence supports similarities between obesity and substance-use disorders in animal models, evidence from human studies is limited ([@bib32]).

Risk-taking abnormalities in disorders of drug and food reward are known to occur under conditions of risk (known probabilities) and uncertainty (unknown probabilities). For example, stimulant-dependent subjects and subjects with binge eating or obesity have impaired decisions using the Iowa gambling task, which addresses risk-taking under uncertainty ([@bib3]; [@bib12]). Chronic amphetamine and alcohol-dependent users show suboptimal decisions under risk with explicit probabilities, on the Cambridge gamble task ([@bib21]; [@bib2]; [@bib11]). Furthermore, subjects with alcohol-use disorders and women with BED also have impaired decision making on the game of dice task ([@bib23]), with known explicit rules and probabilities. Although these tasks assess choices under ambiguous or risky conditions with feedback, they do not address the influences of valence, probability, or value differences.

Here we use an adaptation of a risk task ([@bib17]; [@bib24]) that assesses risk attitude focusing on the effects of valence, probability, and value, without feedback. We hypothesize that these dimensions influence risk-taking in all disorders and that binge eating shows similar deficits to other substance-use disorders. In particular, we expect greater risk-seeking in the reward domain and that loss has divergent influence on risk-taking across all disorders. We further investigate the individual differences of nonlinearity of probability weighting (*α*) with gray matter volume in healthy volunteers (HV).

PATIENTS AND METHODS
====================

Recruitment
-----------

Abstinent subjects with alcohol dependence (EtOH, *N*=30), obese subjects (\>30 body mass index, BMI) with BED (*N*=30), obese controls without BED (*N*=30) and abstinent methamphetamine-dependent subjects (Meth, *N*=23) were recruited for the study. For each subject in each patient group, two age- and gender-matched HV were recruited. For the voxel-based morphometry study, a different sample of 30 HV (mean age 24.15 (SD 2.91); 17 males) underwent scanning. Further recruitment strategy and questionnaires completed have been reported elsewhere ([@bib28]) and are described in [Supplementary Materials](#sup1){ref-type="supplementary-material"}.

Task
----

Subjects chose between a Risky choice (jar with explicit probability of red and blue balls) and a Sure choice ([Figure 1a](#fig1){ref-type="fig"}). Subjects were told that if they chose the Risky choice, the computer would randomly select a ball from the jar. If the ball was red, the subject would win (or lose) the specified amount indicated above the jar. If they chose the Sure choice, they would win (or lose) the full amount indicated. Choices were presented with 4 probabilities (*P*=0.1, 0.3, 0.5, 0.9) and 4 expected values (EV=£10, £50, £100, £500) for each probability, giving 16 prospects. The order of the probabilities and EVs were randomized. Reward and loss conditions were run separately and the order counterbalanced across subjects.

For each prospect the certainty equivalent (CE, the amount of certain money that would be accepted instead of a gamble) was computed. This was determined in a step-wise manner depending on the previous choices ([@bib17]; [@bib24]). The value (V) of the Risky choice (amount indicated over the jar) was calculated as *V*=EV/P (eg, for *P*=0.1, EV=£100, *V*=£1000) ([Figure 1](#fig1){ref-type="fig"}). The CE range for each prospect was determined by defining the range of values between 0 and *V* of the Risky choice (eg, 0--£1000) (described in detail in [Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). In trials 1 and 2, the amount of the Sure choice was the one-third and two-third cut-point values. The interval for the next two trials included only the interval accepted by the subject in the first two trials. For eg, if the subject rejected the lower and middle third, the upper third was used as the range for trials 3 and 4. The amount of the Sure choice was then the one-third and two-third cut-point values of this upper third range. The same process was repeated for trials 5 and 6 and the average of these final choices was used to determine the CE. In the instructions, subjects were given an example trial of six choices to demonstrate the step-wise method and changes in the Sure magnitude. There was no time limit for each trial. The equivalent in US dollars were used for subjects tested in the United States. Subjects were told that they would not find out the outcome after each trial but that at the end of the study, the computer randomly selected one of the trials and they would either receive or lose a proportion of the amount won or lost. The task was coded in e-PRIME 2.0.

The weighted probability, *w(p)*, was calculated according to prospect theory as:

where *v* (*x,p*) is the subjective value of amount *x* at probability *p* (ie, the CE) and *w* is the decision weight of the objective probability *p*.

The estimation of the nonlinearity of probability weighting was calculated using the two-parameter function derived by [@bib19]. The one-parameter function derived by Prelec is described as follows:

with 0\<*α*\<1. Using the one-parameter function, the *w(p)* function is an inverted S-shaped function with a fixed inflection point at *p*=1/e=0.37 (where *p*=*p(w)*). The *α* parameter indicates the degree of nonlinearity with *α* approaching 0 indicating greater nonlinearity and *α* approaching 1 approximating the linear expected value. As we were focusing on pathological groups in which the inflection point may not conform to 1/*e*, we estimated probability weighting using a two-parameter function ([@bib19]) in which the inflection point was not constrained to the 1/*e* fixed value:

*β* indicates the net convexity of the curve. Where *β*=1 is consistent with the one-parameter function where the inflection point crosses at *p*=1/*e*. As *β* approaches 0, the inflection point at which risk-seeking shifts to risk aversion increases occurring at *p*\>1/*e*, indicating greater risk-seeking across a wider range of probabilities. Examples of functions with different *α* and *β* values are shown in [Figure 1](#fig1){ref-type="fig"}. *α* and *β* and the fit *R*^2^ were calculated for each EV. *R*^2^ outliers (\>3 SD from group mean) were removed from the analysis.

Statistical Analysis
--------------------

The *w(p)* was analyzed as a mixed measures ANOVA with Group as a between-subjects factor, and Valence, Probability, and Value as a within-subjects factor. We focused on the main effects and the interaction effects involving the Group factor. We also conducted a *post hoc* analysis comparing Group differences as a function of probability using Tukey\'s test if there was a Group × Probability × Valence interaction to assess the influence of probability.

To assess the relationship with Value, we conducted two separate mixed measures ANOVA since Value was positive in the reward domain and negative in the loss domain. We also conducted a *post hoc* analysis using Tukey\'s test if there was a Group × Value interaction to assess the influence of value.

The *w(p)* for each value for the reward condition were fit with the two-parameter model and *α* and *β* analyzed as a mixed measures ANOVA with Group as a between-subjects factor and value as a within-subjects factor. For all analyses, *P*\<0.05 was considered significant.

We also assessed the relationship of *w(p)* for reward and loss collapsed across probability and value to clinical measures for each subject group using the Pearson correlation. For the BED and obese subjects, the corrected Bonferroni value was *P*\<0.0125 (4 comparisons) and for EtOH and Meth subjects was *P*\<0.008 (6 comparisons).

MRI data acquisition and analysis details are reported in [Supplementary Materials](#sup1){ref-type="supplementary-material"}.

RESULTS
=======

Subject Characteristics
-----------------------

Subject characteristics are reported in [Supplementary Materials S1 and S2](#sup1){ref-type="supplementary-material"}. Three HV, one BED, one EtOH, and two Meth subjects were removed from the analysis as outliers.

For each subject group, the following analyses are divided into: (i) decision weight *w(p)* across probabilities ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}; [Figure 2](#fig2){ref-type="fig"}); (ii) *w(p)* separately for reward and loss across values ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}; [Figure 3](#fig3){ref-type="fig"} and [Figure 4](#fig4){ref-type="fig"}); (iii) nonlinearity, *α*, and convexity, *β* [Supplementary Table S5](#sup1){ref-type="supplementary-material"}; [Figure 5](#fig5){ref-type="fig"}).

Obese Subjects with BED
-----------------------

### Decision weight, w(p): probability

A main Group effect revealed that BED overweighted probabilities compared with HV. The Group × Valence interaction showed greater risk-taking in reward (mean difference −0.100 (SEM 0.03) (95% CI: −0.161 to −0.039), *p*=0.002) but not loss (0.020 (SEM 0.034) (95% CI: −0.047--0.087), *p*=0.553). There was a main Probability and Value effect and Group × Probability and Group × Probability × Valence interactions. On *post hoc* analysis, BED made more risky choices to moderate probabilities (*P*=0.30 and 0.50) in reward and more risky choices to high probabilities (*P*=0.90) in loss.

### Decision weight, w(p): value

Reward: there was a main Group, Probability, and Value effect. There was a Group × Value interaction in which there was a Value effect in HV (F(3,86)=12.036, *p*\<0.001) but not in BED (F(3,86)=1.199, *p*=0.315). Loss: there was a main Probability and Value effect only.

### Reward nonlinearity (α) and convexity (β)

For *β*, there was a main Group effect: BED made more risky choices (lower *β*) compared with HV (*R*^2^: HV 0.57 (0.39), BED 0.51 (0.33), *t*=0.51, *p*=0.59). There was a main Probability effect. For *α*, there was a main Probability effect.

Obese Controls Without BED
--------------------------

### Decision weight, w(p): probability

There was a main Probability, Value, and Valence effect and a Group × Probability and Group × Probability × Valence effect. On *post hoc* analysis, during loss, obese controls made fewer risky choices to low probabilities (*P*=0.10 and 0.30) and more risky choices to high probabilities (*P*=0.90).

### Decision weight, w(p): value

There was a main Probability and Value effect. During loss, there was a main Probability and Value effect.

### Reward nonlinearity (α) and convexity (β)

For *β* and *α*, there was a main Probability effect but not of Group or an interaction. (*R*^2^: HV 0.56 (0.40), obese 0.47 (0.41), *t*=1.154, *p*=0.253.)

Abstinent Alcohol-Dependent Subjects
------------------------------------

### Decision weight, w(p): probability

A main Group effect revealed that EtOH subjects overweighted probabilities compared with HV in reward (mean difference −0.074 (SEM 0.033) (95% CI: −0.139 to −0.010), *p*=0.025) but not in loss (mean difference −0.015 (SEM 0.032) (95% CI: −0.078--0.048), *p*=0.639). There was a main Probability and Value effect and Group × Probability and Group × Probability × Valence interaction. On *post hoc* analysis, EtOH subjects made more risky choices to moderate probabilities (*P*=0.50) to reward and to high probability (*P*=0.90) to loss along with fewer risky choices to low probability (*P*=0.10) to loss.

### Decision weight, w(p): value

Reward: there was a main Group, Probability, and Value effect. Loss: there was a main Probability effect.

### Reward nonlinearity (α) and convexity (β)

For *β*, there was a main Group effect: EtOH made more risky choices (lower *β*) compared with HV (*R*^2^: HV 0.53 (0.40), EtOH 0.56 (0.26), *t*=−0.35, *p*=0.72). There was a main Value effect. For *α*, there were no main or interaction effects.

Abstinent Stimulant-Dependent Subjects
--------------------------------------

### Decision weight, w(p): probability

A main Group effect demonstrated that Meth subjects overweighted probabilities compared with HV in reward (mean difference −0.97 (SEM 0.038) (95% CI: −0.172 to −0.022), *p*=0.012) and not in loss (mean difference=0.029 (SEM 0.035) (95% CI: −0.099--0.041), *p*=0.413). There was a main Probability effect and Group × Probability and Group × Value interaction. On *post hoc* analysis, Meth subjects made more risky choices to low probability (*P*=0.10 and 0.30) in reward and to high probability (*P*=0.90) in loss along with fewer risky choices to low probability (*P*=0.10) in loss.

### Decision weight, w(p): value

Reward: there was a main Group, Probability, and Value and Group × Value interaction effect in which Value was significantly different in HV (F(3,65)=7.207, *p*\<0.001) but not in Meth (F(3,65)=1.560, *p*=0.206). Loss: there was a main Group and Probability effect only.

### Reward nonlinearity (α) and convexity (β)

For *β*, there was a main Group effect: Meth made more risky choices (lower *β*) compared with HV (*R*^2^: HV 0.52 (0.40), Meth 0.40 (0.37), *t*=1.31, *p*=0.19). There was an interaction effect. For *α*, there was a Group effect: Meth had greater nonlinearity (lower *α*) compared with HV. There was a main effect of Value.

Nicotine
--------

Although the study was not intended to address nicotine effects, analyses were conducted on an exploratory basis focusing on *w(p)* for probability ([Supplementary Materials](#sup1){ref-type="supplementary-material"}). Ex-smokers (*N*=25) in the combined group of obese, BED, and HV, made fewer risky choices than non-smokers (*N*=82) (F(1,103)=4.276, *p*=0.041), with no differences between current smokers (*N*=24) and non-smokers (*N*=82) (F(1,102)=1.471, *p*=0.228) ([Figure 3](#fig3){ref-type="fig"}).

Relationship to Clinical Measures
---------------------------------

We also assessed the relationship of *w(p)* to clinical measures. For BED only, BES scores were positively correlated with *w(p)* for reward (Pearson\'s correlation coefficient=0.498, *p*=0.007) and negatively correlated for loss (−0.509, *p*=0.006) (Bonferroni-corrected *P*\>0.0125) ([Figure 3](#fig3){ref-type="fig"}). There were no correlations with BMI. For EtOH, there was a negative correlation trend between weeks abstinent and *w(p)* for reward (−0.417, *p*=0.024) but not loss (0.036, *p*=0.850). There were no significant correlations with duration or total units (Bonferroni-corrected *P*\>0.008). For Meth there was a negative correlation trend with number of years of heavy use and *w(p)* for reward (−0.487, *p*=0.022) but not loss (0.143, *p*=0.523) (Bonferroni-corrected *P*\>0.008). There were no significant correlations between *w(p)* and BDI for any group (*p*\>0.05).

Structural Correlates of Nonlinearity
-------------------------------------

In 30 HV, gray matter volume was positively correlated with *α* in the right dorsolateral prefrontal cortex (DLPFC) (reported in MNI coordinates *x y z* in mm=33 50 36, cluster size=18, *Z*=5.18, whole-brain FWE-corrected *P*=0.009, BA 9), left ventromedial prefrontal cortex (vmPFC) (*x y z* in mm: −4 44 −18, cluster size=33, *Z*=4.94, whole-brain FWE-corrected *P*=0.02, BA 11, [Figure 1d](#fig1){ref-type="fig"}) and right medial orbitofrontal cortex (mOFC) (*x y z* in mm: 15 30 −18, cluster size=17, *Z*=4.98, whole-brain FWE-corrected *P*=0.02, BA 11).

DISCUSSION
==========

We demonstrate that risk attitude across disorders of addiction varies according to the currently manipulated dimensions of valence (gain and loss), probability, and value (magnitude). In the reward domain, obese subjects with binge eating have enhanced risk-seeking similar to that of substance-use disorders, with the degree of risk-seeking in the reward domain correlating with binge eating severity. In contrast, in the loss domain, obese subjects without binge eating have a similar risk attitude to substance-use disorders with greater risk aversion to unlikely large losses and greater risk-seeking to likely small losses. On the influence of value, obese subjects with binge eating also have a similar impairment to that of the Meth subjects, particularly in their discrimination of subjective value. These findings further explain the abnormalities in risk-taking observed in obese individuals ([@bib18]), and more importantly highlight the similarities in disorders characterized by natural and drug rewards. In terms of probability, methamphetamine-dependent subjects have greater risk-seeking to unlikely but large rewards along with greater nonlinearity of probability weighting (lower *α*), and BED and alcohol-dependent subjects have greater risk-seeking to more likely but smaller rewards. Although not a direct correlate, this differential attitude toward reward probability may underlie choice tendencies toward the degree of risk or 'high\' of illegal or legal drugs or natural rewards. These tendencies may combine with enhanced 'waiting\' impulsivity in the alcohol- and methamphetamine-dependent subjects ([@bib29]) to drive risky decisions in pathological choices toward natural and drug rewards.

The relationship between obesity and disorders of substance addiction has recently been of great interest. In keeping with the preclinical literature on sugar bingeing in rodents, binge eating, rather than obesity *per se*, may have closer overlaps with substance-use disorders. In rodents, sugar bingeing reflects addictive-like properties including enhanced responding for sugar after abstinence, amphetamine cross-sensitization and nucleus accumbens dopamine release ([@bib1]). In humans, food stimulation in BED subjects is also associated with greater striatal dopamine release ([@bib31]). Thus, our data on risk attitude in the reward domain dovetails with these observations suggesting similarities in enhanced risk-seeking between binge eating and substance dependence.

In the context of loss, obese subjects without BED and alcohol- and stimulant-dependent subjects are all more risk averse to low probability losses and more risk-seeking to high probability losses. These results might explain the coexistence of conflicting risk attitudes influenced by context: risky addictive behaviors to avoid likely small negative outcomes and simultaneously, risk aversion in the anticipation of unlikely large negative outcomes. Our finding of enhanced sensitivity to loss anticipation dovetails with heightened sensitivity to negative cues (such as negative mood, stress, or withdrawal), which may act as a negatively reinforcing motivator in substance-use disorders and compulsive overeating ([@bib10]). As expected in HV, normal responses to loss are demonstrated by risk aversion to low probability losses and risk-seeking to higher probability losses. Our findings in the pathological groups suggest an enhancement of this underlying tendency.

Whereas previous tasks involved feedback, our current task focuses on risk anticipation without feedback emphasizing the predictive nature of risk anticipation. In a study focusing on risk-taking under uncertainty using the Iowa gambling task, both BED and obese controls were equally impaired ([@bib3]). In contrast, in a study focusing on explicit risk using the game of dice task, BED had greater risk-taking relative to obese controls ([@bib23]). Our results are convergent with these findings suggesting that BED may be impaired at risky choices under risk and ambiguity but obese subjects without BED may be impaired only under ambiguity. The impairment under ambiguity in BED has been shown to be related to depression ([@bib15]). Studies in substance-use disorders have similarly demonstrated risk-taking abnormalities in tasks with both ambiguity and explicit risk ([@bib21]; [@bib2]; [@bib11]; [@bib3]; [@bib12]). Unlike this current study, these previous studies do not address differences in probability, valence, or value.

We show that enhanced nonlinearity of probability weighting (lower *α*) in HV is associated with lower gray matter volume in left vmPFC, right mOFC, and right DLPFC, consistent with regions implicated in the representation and evaluation of risk and probability ([@bib4]; [@bib26]; [@bib20]). Greater nonlinearity of probability weighting is believed to be associated with impaired discrimination of different probabilities ([@bib24]), which dovetails with our findings of decreased gray matter volume in the vmPFC and OFC. The curvature of the weighting function has been postulated to be related to the psychophysics of diminishing sensitivity or affective influences such as hope or fear related to the gamble ([@bib27]). We further show that Meth subjects have greater nonlinearity of probability weighting (lower *α*, ie, overweighting of low probabilities and underweighting of high probabilities) to anticipated risky rewards. Methamphetamine dependence has been associated with decreased OFC volume ([@bib16]) possibly related to comorbid nicotine use ([@bib14]). Abstinent stimulant-use disorder subjects have also been shown to have decreased mOFC volumes ([@bib5]), associated with impaired decisions in a modified gambling task ([@bib25]). Although we did not show abnormalities in *α* in BED subjects, OFC-volume differences have also been reported ([@bib22]; [@bib30]).

Subjective value was assessed by comparing the *w(p)* across the highest and lowest values within each group. As expected, HV exhibited a decrease in subjective value equivalent to diminishing marginal sensitivity with increasing objective value ([@bib9]). BED and Meth subjects did not demonstrate any differences in subjective value with increasing objective value. This can be interpreted as decreased sensitivity toward changes in magnitude, which coincides with reports of decreased sensitivity to changes in value in stimulant users. Psychostimulant-dependent subjects show decreased subjective discrimination of monetary reward gradients ([@bib6]), and decreased reaction times and lateral orbitofrontal responsivity to monetary reward outcomes ([@bib7]).

Although exploratory, we show that ex-smokers had lower risk-taking in the reward domain than non-smokers. These findings suggest either that the lack of nicotine is associated with lower risk-taking or more likely, that the ability to stop smoking may be related to lower risk-taking tendencies. In the case of obese ex-smokers, lower risk-taking for rewards may also reflect the shift from exogenous nicotine drug use toward endogenous natural rewards.

There were several limitations to the study. Relative to HV, Meth, BED, and EtOH subjects had higher depression scores as commonly reported in studies on substance-use disorders and in relation to this current cohort ([@bib28]). However, we show that IQ and depression scores are unrelated to the current measures. As this is a cross-sectional study, we cannot address the question of whether risk attitude is a state or trait-related factor. Unlike subjects with substance-use disorders, the obese subjects were not 'abstinent\' or food restricted, which may affect motivational states. The influence of food restriction is baseline dependent such that it decreases risk aversion in those who are risk-seeking and increases risk-seeking in those who are risk averse ([@bib13]). How food restriction might affect obese subjects should be assessed. We use a similar secondary reinforcer across all groups to allow for comparisons. The use of primary reinforcers are indicated to assess any differential influence on risk-taking.

We show that risk-taking is heterogeneous and pathological choices can be influenced by factors of valence, probability, and magnitude. Our data uniquely highlight the overlaps between the behavior of binge eating and substance-use disorders in the reward domain and obesity and substance-use disorders in the loss domain. BED subjects similar to stimulant disorder subjects were also impaired in discrimination of subjective value. These characterizations are of particular importance as we have recently shown that an expected risk factor of 'waiting\' impulsivity is not disturbed in obese patients with and without BED ([@bib29]). Our findings support mechanistically based dimensional rather than categorical approaches to psychiatric classifications ([@bib8]) and suggest valence-specific modification of risk perception as a potential therapeutic avenue.
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![(a) Risk task. Subjects chose between a gamble and sure choice in both reward and loss conditions across 4 probabilities (0.1, 0.3, 0.5, 0.9) and 4 expected values (£10, £50, £100, £500). A staircase procedure was used to estimate the gamble\'s certainty equivalents (amount of sure payoff in subject indifferent between sure payoff and gamble). (b) Examples of functions with different nonlinear (*α*) and convexity (*β*) values. (c) Probability weighting, *w(p)*, data of healthy volunteers (HV) in reward condition as a function of objective probability, *p*. The dotted line represents certainty equivalence=expected value. (d) Regression analysis of gray matter volume and *α*. The regression represents left ventromedial prefrontal cortex as a function of *α*.](npp2014242f1){#fig1}

![Probability weighting in pathological disorders in reward and loss conditions. The graphs compare probability weighting, *w(p)*, in obese subjects with binge eating disorder (BED) and without BED (obese controls), abstinent alcohol-dependent (EtOH) and abstinent methamphetamine-dependent (Meth) *vs* their own age- and gender-matched controls for reward (top) and loss (bottom) conditions. The dotted line represents certainty equivalence=expected value. Error bars represent SEM. \**Post hoc* analysis results following interaction effect of Group × Valence × Probability. Details of significant differences are described in the text and [Supplementary Table S3](#sup1){ref-type="supplementary-material"}. *P*=probability.](npp2014242f2){#fig2}

![Left: probability weighting as a function of current smokers, ex-smokers, and non-smokers in healthy volunteers (HV), and obese subjects with and without binge eating disorder. \**P*\<0.05 Group difference between ex-smokers and non-smokers. Right: relationship with clinical variables. Obese subjects with binge eating disorder: relationship between binge eating severity (BES) and probability weighting, *w(p)*, in the reward and loss domains.](npp2014242f3){#fig3}

![Probability weighting as a function of reward value. The graphs compare probability weighting, *w(p)*, and value in the reward domain in obese subjects with binge eating disorder (BED) and without BED (obese controls), abstinent alcohol-dependent (EtOH) and abstinent methamphetamine-dependent (Meth) subjects *vs* their own age- and gender-matched controls. Error bars represent SEM. \*Group × Value interaction. Details of significant differences are described in the text and [Supplementary Table S4](#sup1){ref-type="supplementary-material"}. HV, healthy volunteers; Stim, abstinent stimulant dependent.](npp2014242f4){#fig4}

![Convexity (*β*) and nonlinearity (*α*). The graphs compare convexity (*β*; top) and nonlinearity (*α*; bottom) in obese subjects with binge eating disorder (BED) and without BED (obese controls), abstinent alcohol-dependent (EtOH) and abstinent methamphetamine-dependent (Meth) subjects *vs* their own age- and gender-matched controls. Error bars represent SEM. \*Main Group effect. Details of significant differences are described in the text and [Supplementary Table S5](#sup1){ref-type="supplementary-material"}. HV, healthy volunteers; Stim, abstinent stimulant dependent.](npp2014242f5){#fig5}
